Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 596Lung Neoplasms 187Neoplasms 66Neoplasm Metastasis 46Mesothelioma, Malignant 45Adenocarcinoma of Lung 41Mesothelioma 39Colorectal Neoplasms 29Carcinoma 23Breast Neoplasms 23Parkinson Disease 4, Autosomal Dominant Lewy Body 21Meningeal Carcinomatosis 19Head and Neck Neoplasms 19Brain Neoplasms 18Ovarian Neoplasms 17Adenocarcinoma 15Small Cell Lung Carcinoma 14NSCLC 14Pancreatic Neoplasms 12Melanoma 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Lung Diseases 10Carcinoma, Transitional Cell 10Uterine Cervical Neoplasms 9Neoplasms by Site 9Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Cancers × Pemetrexed × Clear all
NCT01301716 2016-11-02

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Genentech, Inc.

Phase 1 Completed
75 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡